| |
Use of GLP-1 mimetic in type 2 diabetes mellitus: is it the end of fragility fractures?
- 作者:Guillaume Mabilleau (1) (2)
1. GEROM Groupe Etudes Remodelage Osseux et bioMat茅riaux 鈥?UPRES EA 4658 LHEA ; IRIS-IBS Institut de Biologie en Sant茅 ; CHU d鈥橝ngers ; LUNAM Universit茅 ; 4 rue Larrey ; 49933 ; Angers Cedex 09 ; France 2. SCIAM ; Service Commun d鈥橧magerie et Analyses Microscopiques ; IRIS-IBS Institut de Biologie en Sant茅 ; CHU d鈥橝ngers ; LUNAM Universit茅 ; 49933 ; Angers Cedex ; France
- 刊名:Endocrine
- 出版年:2015
- 出版时间:February 2015
- 年:2015
- 卷:48
- 期:1
- 页码:1-2
- 全文大小:86 KB
- 参考文献:1. L.L. Baggio, D.J. Drucker, Biology of incretins: GLP-1 and GIP. Gastroenterology 132, 2131鈥?157 (2007) dx.doi.org/10.1053/j.gastro.2007.03.054" target="_blank" title="It opens in new window">CrossRef
2. C.F. Deacon, A.H. Johnsen, J.J. Holst, Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J. Clin. Endocrinol. Metab. 80, 952鈥?57 (1995) 3. G. Mabilleau, A. Mieczkowska, N. Irwin, P.R. Flatt, D. Chappard, Optimal bone mechanical and material properties require a functional glucagon-like peptide-1 receptor. J. Endocrinol. 219, 59鈥?8 (2013) dx.doi.org/10.1530/JOE-13-0146" target="_blank" title="It opens in new window">CrossRef 4. M. Monami, I. Dicembrini, A. Antenore, E. Mannucci, Dipeptidyl peptidase-4 inhibitors and bone fractures: a meta-analysis of randomized clinical trials. Diabetes Care 34, 2474鈥?476 (2011) dx.doi.org/10.2337/dc11-1099" target="_blank" title="It opens in new window">CrossRef 5. J.H. Driessen, H.A. van Onzenoort, R.M. Henry, A. Lalmohamed, J.P. van den Bergh, C. Neef et al., Use of dipeptidyl peptidase-4 inhibitors for type 2 diabetes mellitus and risk of fracture. Bone 68, 124鈥?30 (2014) dx.doi.org/10.1016/j.bone.2014.07.030" target="_blank" title="It opens in new window">CrossRef 6. G. Mabilleau, A. Mieczkowska, D. Chappard, Use of glucagon-like peptide-1 receptor agonists and bone fractures: a meta-analysis of randomized clinical trials. J Diabetes 6, 260鈥?66 (2014) dx.doi.org/10.1111/1753-0407.12102" target="_blank" title="It opens in new window">CrossRef 7. B. Su, H. Sheng, M. Zhang, L. Bu, P. Yang, L. Li et al., Risk of bone fractures associated with glucagon-like peptide-1 receptor agonists鈥?treatment: a meta-analysis of randomized controlled trials. Endocrine (2014). doi:10.1007/s12020-014-0361-4 8. T. Mancini, G. Mazziotti, M. Doga, R. Carpinteri, N. Simetovic, P.P. Vescovi et al., Vertebral fractures in males with type 2 diabetes treated with rosiglitazone. Bone 45, 784鈥?88 (2009) dx.doi.org/10.1016/j.bone.2009.06.006" target="_blank" title="It opens in new window">CrossRef 9. G. Mazziotti, A. Bianchi, S. Bonadonna, V. Cimino, I. Patelli, A. Fusco et al., Prevalence of vertebral fractures in men with acromegaly. J. Clin. Endocrinol. Metab. 93, 4649鈥?655 (2008) dx.doi.org/10.1210/jc.2008-0791" target="_blank" title="It opens in new window">CrossRef 10. G. Mazziotti, A. Bianchi, S. Bonadonna, M. Nuzzo, V. Cimino, A. Fusco et al., Increased prevalence of radiological spinal deformities in adult patients with GH deficiency: influence of GH replacement therapy. J. Bone Miner. Res. 21, 520鈥?28 (2006) dx.doi.org/10.1359/jbmr.060112" target="_blank" title="It opens in new window">CrossRef
- 刊物主题:Endocrinology; Diabetes; Internal Medicine; Science, general;
- 出版者:Springer US
- ISSN:1559-0100
| |
NGLC 2004-2010.National Geological Library of China All Rights Reserved.
Add:29 Xueyuan Rd,Haidian District,Beijing,PRC. Mail Add: 8324 mailbox 100083
For exchange or info please contact us via email.
| |